Home India Ministry of Chemicals and Fertilizers Parliament Question: Domestic Pharmaceutical Manufacturers...
Date: 2026-07-31 Category: LOKSABHA_QNA State: Union Government Country: India

Parliament Question: Domestic Pharmaceutical Manufacturers

Issued by Ministry of Chemicals and Fertilizers · Not Applicable

Research with AI Agent Chat with Document Generate Summary Translate Helpful Share Add to Project Create Task
Official Source Record View Original Source →
See Full Document Text
GOVERNMENT OF INDIA MINISTRY OF CHEMICALS AND FERTILIZERS DEPARTMENT OF PHARMACEUTICALS LOK SABHA UNSTARRED QUESTION NO. 2258 TO BE ANSWERED ON THE 31st JULY, 2026 Domestic Pharmaceutical Manufacturers 2258. Shri Robert Bruce C: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state: (a) the total number of domestic pharmaceutical manufacturers that have successfully registered their production lines on the newly launched Form IA central digital pricing database, batch-wise; and (b) the details of the penal actions initiated by the National Pharmaceutical Pricing Authority (NPPA) against distributors for overcharging or artificial retail stock withholding across Tamil Nadu during the last four months? ANSWER THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SMT. ANUPRIYA PATEL) (a): As per the Drugs (Prices Control) Amendment Order, 2026 notified by the Department of Pharmaceuticals (DoP) vide S.O. 3516 (E) dated 30th June 2026, any existing manufacturer producing the same new drug formulation whose retail price has been notified by NPPA in preceding twelve months is required to follow the same retail price and intimate to NPPA under Form-1A within one month from the date of launch. Form-IA does not mandate registering the production lines or batches by the domestic pharmaceutical manufacturers. (b): The National Pharmaceuticals Pricing Authority (NPPA) is entrusted with implementation of Drugs Price Control Order issued by the DoP, from time to time. NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013 and takes action against manufacturers found overcharging the consumers, based on the references received from various resources including Price Monitoring and Resource Units (PMRUs), State Drugs Controllers, samples purchased from the open market, reports from market data base, complaints reported through the grievance redressal channels. The suspected cases of overcharging received from above sources are examined and in case a prima facie case of overcharging is made out, action is initiated as per provisions of DPCO, 2013. During the last four months, NPPA has issued 103 demand notices to manufacturers across the country including Tamil Nadu. Further, NPPA does not maintain state-wise record of overcharging by pharmaceutical companies. *****

Continue your research